We have updated our myocarditis and pericarditis following COVID-19 vaccines page to reflect the guidance by the Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ).
ATAGI and CSANZ emphasise that the overwhelming benefits of vaccination in protecting against COVID-19 greatly outweigh the rare risk of these conditions, and Comirnaty (Pfizer mRNA vaccine) continues to be recommended for all people ≥ 16 years of age who do not have any contraindications to the vaccine, in those aged 12-15 with specific medical conditions that increase their risk of severe illness from COVID-19, and in Aboriginal and Torres Strait Islanders aged 12-15.
要了解更多信息，请参阅下面链接中的专门针对 COVID-19 疫苗接种后的 MVEC 心肌炎和心包炎页面。
MVEC myocarditis and pericarditis following COVID-19 vaccines page